Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
NCT00437294 · Eli Lilly and Company · PHASE2 · terminated · last registry update 2020-08-10 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PRKCB in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-24Results posted on the registry: Eli Lilly and Company, Enzastaurin + Bevacizumab (NCT00536939)
- 2020-09-24Also stopped (terminated): Eli Lilly and Company, Enzastaurin + Bevacizumab (NCT00536939)
- 2019-11-01Results posted on the registry: Eli Lilly and Company, enzastaurin + placebo (NCT00451555)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision